JTT 302
Alternative Names: JTT-302Latest Information Update: 08 Aug 2013
At a glance
- Originator Japan Tobacco
 - Class Antihyperlipidaemics
 - Mechanism of Action Cholesterol ester transfer protein inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Discontinued Hyperlipidaemia
 
Most Recent Events
- 30 Jul 2013 Discontinued - Phase-II for Hyperlipidaemia (PO)
 - 27 Apr 2007 Phase-II clinical trials in Hyperlipidaemia (PO)
 - 18 Apr 2005 Phase-I clinical trials in Hyperlipidaemia (PO)